Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767787 | 1.00 | KMT2A (0.45) | KMT2AMEN1SMYD3POLBPRCP | |
| Hydrochloric Acid SCHEMBL27646595 | 0.98 | KMT2A (0.47) | KMT2AMEN1SMYD3POLBPRCP | |
| Hydrochloric Acid SCHEMBL1509727 | 0.98 | KMT2A (0.47) | KMT2AMEN1SMYD3POLBPRCP | |
| Hydrochloric Acid SCHEMBL31263635 | 0.78 | KMT2A (0.43) | KMT2AMEN1SMYD3POLBPRCP | |
| SCHEMBL29350565 | 0.78 | GAA (0.58) | KMT2AMEN1PRCPOPRM1OPRD1 | |
| SCHEMBL29350888 | 0.78 | GAA (0.58) | KMT2AMEN1PRCPOPRM1OPRD1 | |
| SCHEMBL43168 | 0.78 | GAA (0.58) | KMT2AMEN1PRCPOPRM1OPRD1 | |
| SCHEMBL29398238 | 0.78 | GAA (0.58) | KMT2AMEN1PRCPOPRM1OPRD1 | |
| SCHEMBL288272 | 0.78 | GAA (0.58) | KMT2AMEN1PRCPOPRM1OPRD1 | |
| SCHEMBL288260 | 0.78 | GAA (0.58) | KMT2AMEN1PRCPOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | KMT2A 1337/4885MEN1 3738/4885SMYD3 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.